AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 25746294
Drug: 24 days
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 24 days of 3mg drospirenone (DRSP)/20 mcg EE, followed by 4 placebo (PBO)‐pill days (DRSP/EE+4 days PBO)
Trial: 25746294
Drug: 21 days
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 21 days of 100 mcg levonorgestrel (LNG)/20 mcg EE, followed by 7 PBO‐pill days (LNG/EE+7 days PBO)
Trial: 21453379
Drug: Adapted U.S.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adapted U.S. model of pharmaceutical care (n=128)
Trial: 11416745
Drug: 200 ml
RxNorm normalized name: Bag Top-Fill, 1200 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 ml milk before exercise SPECT and after injection for rest SPECT acquisition (Group B) plus a standard solid and fluid meal
Trial: 11416745
Drug: 200 ml
RxNorm normalized name: Bag Top-Fill, 1200 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 ml milk before exercise SPECT and after injection for rest SPECT acquisition (Group A)
Trial: 8440858
Drug: Physical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical therapy sessions three times weekly for 4 months, lasting 30 minutes each, consisting of functional activity and general conditioning exercises tailored to individual needs.
Trial: 8440858
Drug: Physical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical therapy sessions three times weekly for 4 months.
Trial: 8440858
Drug: Structured social
RxNorm normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Structured social visits three times weekly to control for potential Hawthorne effects.
Trial: 8440858
Drug: Physical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical therapy intervention costs and incremental health care utilization.
Trial: 24956971
Drug: Chlorthalidone (12.5-25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorthalidone (12.5-25 mg daily, group D)
Trial: 24956971
Drug: Other antihypertensive
RxNorm normalized name: Other antihypertensives
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other antihypertensive medications (group A)
Trial: 16487390
Drug: Active medication
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active medication (ranitidine plus cisapride)
Trial: 12871446
Drug: Enoxaparin 40
RxNorm normalized name: ENOXAPARIN 40MG/0.4ML INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin 40 mg daily subcutaneous injections
Trial: 10831196
Drug: Lidocaine 4%
RxNorm normalized name: Lidocaine 4% Patch
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine 4% solution
Trial: 8018455
Drug: 0.04 mg
RxNorm normalized name: sulfur 0.04 MG/MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.04 mg kg‐1 enalaprilat (low‐dose, n = 10)
Trial: 8018455
Drug: 0.08 mg
RxNorm normalized name: mestranol 0.08 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.08 mg kg‐1 enalaprilat (high‐dose, n = 10)
Trial: 8018455
Drug: Saline solution
RxNorm normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline solution as placebo (control group, n = 10)
Trial: 30747745
Drug: Magnesium sulfate
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Magnesium sulfate administration for longer than 18 hours, given within 12 hours of delivery, maintaining a maternal serum level of 4.1 mg/dl.
Trial: 25417403
Drug: Fuzi-cake-separated moxibustion
RxNorm normalized name: serrated swimming crab, cooked preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fuzi-cake-separated moxibustion at Guanyuan (CV 4) and Zhongji (CV 3), 20 min twice a day for 3 days before operation
Trial: 19243424
Drug: Eslicarbazepine acetate
RxNorm normalized name: Eslicarbazepine Acetate
DrugBank: Eslicarbazepine (DB14575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eslicarbazepine acetate 1,200 mg
Trial: 11170945
Drug: Clinafloxacin (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinafloxacin (200 mg every 12 h)
Trial: 11170945
Drug: Imipenem (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipenem (500 mg every 6 h)
Trial: 2382874
Drug: Adenosine inhalation
RxNorm normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adenosine inhalation tests on day A
Trial: 2382874
Drug: Saline inhalation
RxNorm normalized name: Broncho Saline Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline inhalation test on day B
Trial: 2382874
Drug: Methacholine inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methacholine inhalation tests on day C
Trial: 7362945
Drug: Prophylactic clindamycin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic clindamycin, 150 mg 6-hourly for 5 days
Trial: 31706052
Drug: Alendronate (70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alendronate (70 mg weekly) + daily elemental calcium (500 mg) + cholecalciferol (1000 IU)
Trial: 31706052
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (daily elemental calcium (500 mg) + cholecalciferol (1000 IU) only)
Trial: 21836511
Drug: sirolimus, mycophenolate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sirolimus, mycophenolate mofetil and steroids
Trial: 19680260
Drug: Azelnidipine (first-line
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azelnidipine (first-line therapy)
Trial: 11159250
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of 0.125% bupivacaine with clonidine 1 microg/mL and sufentanil 0.1 microg/mL at 10 mL/h (Group 1)
Trial: 11159250
Drug: PCA boluses
RxNorm normalized name: lauryl PCA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCA boluses of 10 mL/h of 0.125% bupivacaine with clonidine 1 microg/mL and sufentanil 0.1 microg/mL (Group 2)
Trial: 11159250
Drug: PCA boluses
RxNorm normalized name: lauryl PCA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCA boluses of 5 mL per 30 min of 0.125% bupivacaine with clonidine 1 microg/mL and sufentanil 0.1 microg/mL (Group 3)
Trial: 9626725
Drug: Collaborative management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Collaborative management programme including patient education, on-site mental health treatment, adjustment of antidepressant medication, behavioural activation and monitoring of medication adherence
Trial: 21969666
Drug: Sequential scanning
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential scanning in group A
Trial: 21969666
Drug: Sequential scanning
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential scanning in group B
Trial: 21969666
Drug: Narrow-window prospective
RxNorm normalized name: narrowleaf marshelder pollen extract
DrugBank: Iva angustifolia pollen (DB10968)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Narrow-window prospective sequential scanning in group A
Trial: 21969666
Drug: Wide-window prospective
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wide-window prospective sequential scanning in group B
Trial: 18847416
Drug: New immunosuppressive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New immunosuppressive drugs (specific drugs not mentioned)
Trial: 18847416
Drug: Low-dose or
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose or calcineurin inhibitor-free regimens
Trial: 8958267
Drug: Standard immunosuppression
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard immunosuppression (cyclosporine and steroids)
Trial: 1540881
Drug: Combination chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination chemotherapy with 5‐fluorouracil (5‐FU), doxorubicin, and mitomycin C (FAM)
Trial: 1540881
Drug: Sequential chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential chemotherapy with mitomycin C, followed by doxorubicin on disease progression, followed by 5‐FU
Trial: 1540881
Drug: Secondary therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Secondary therapy with doxorubicin alone
Trial: 1540881
Drug: Tertiary therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tertiary therapy with 5‐FU alone
Trial: 1540881
Drug: Combination chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination chemotherapy (FAM)
Trial: 26093535
Drug: High-dose green
RxNorm normalized name: acid green 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose green tea extract (EGCG) at a daily dosage of 856.8 mg
Trial: 26093535
Drug: High-dose green
RxNorm normalized name: acid green 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose green tea extract (EGCG)
Trial: 24925303
Drug: Galacto‐oligosaccharides (GOS)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Galacto‐oligosaccharides (GOS) (2·5 g; three times per d) during and 7 d after AMX treatment
Trial: 24925303
Drug: Placebo (maltodextrin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (maltodextrin, n 6) (2·5 g; three times per d) during and 7 d after AMX treatment
Trial: 9347244
Drug: Acarbose 100
RxNorm normalized name: acarbose 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acarbose 100 mg t.i.d.
Trial: 8131533
Drug: Oxygen (O2,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxygen (O2, 6 L/min by nasal cannula)
Trial: 2480147
Drug: Placebo (saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (saline infusion for 45 min)
Trial: 30446246
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg atorvastatin before primary angioplasty (AST)
Trial: 18661524
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment alone (ST)
Trial: 25731907
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment (CWMT and BPT)
Trial: 23518863
Drug: 52.5 mL
RxNorm normalized name: ALCOHOL 352.5 mL in 500 mL EXTRACORPOREAL LIQUID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 52.5 mL of lidocaine 1%
Trial: 23518863
Drug: 35 mL
RxNorm normalized name: ethanol 0.35 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 35 mL of lidocaine 1.5%
Trial: 23518863
Drug: 26.25 mL
RxNorm normalized name: ALCOHOL 26.25 mL TOPICAL CLOTH [Sanitizing Wipes]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 26.25 mL of lidocaine 2%
Trial: 18316985
Drug: Separate DTaP
RxNorm normalized name: Atractylis separate root
DrugBank: Atractylodes lancea root (DB14693)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Separate DTaP + IPV vaccines
Trial: 17137891
Drug: Midodrine hydrochloride
RxNorm normalized name: Midodrine Hydrochloride
DrugBank: Midodrine (DB00211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Midodrine hydrochloride as first‐line therapy in addition to conventional therapy
Trial: 9200283
Drug: Bismuth-based triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bismuth-based triple therapy (n = 50)
Trial: 30153497
Drug: Potentially Inappropriate
RxNorm normalized name: Potentilla discolor whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Potentially Inappropriate Psychotropic drugs (PIP)
Trial: 30153497
Drug: Inappropriate background
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inappropriate background regimen prescription
Trial: 30153497
Drug: Inappropriate antidepressant
RxNorm normalized name: ANTIDEPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inappropriate antidepressant prescription
Trial: 30153497
Drug: Inappropriate prescription
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inappropriate prescription of anxiolytics
Trial: 30153497
Drug: Inappropriate prescription
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inappropriate prescription of hypnotics
Trial: 30153497
Drug: Potentially inappropriate
RxNorm normalized name: Potentilla discolor whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Potentially inappropriate background regimen prescription
Trial: 29202646
Drug: 5 mg/1
RxNorm normalized name: Iron 15 MG/1 ML Oral Syrup
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/1 mL diclofenac HPβCD
Trial: 29202646
Drug: 12.5 mg/1
RxNorm normalized name: pyrilamine 12.5 mg/15 mL oral liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12.5 mg/1 mL diclofenac HPβCD
Trial: 29202646
Drug: 25 mg/1
RxNorm normalized name: Levofloxacin 25 MG/1 ML Oral Syrup
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg/1 mL diclofenac HPβCD
Trial: 29202646
Drug: 50 mg/1
RxNorm normalized name: Elimite 50 MG/1GM Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg/1 mL diclofenac HPβCD
Trial: 29202646
Drug: 1 mL
RxNorm normalized name: ethanol 1 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mL placebo
Trial: 20298651
Drug: 10% sucrose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% sucrose solution
Trial: 24636395
Drug: Vitamin D3,
RxNorm normalized name: Vitamin D3, 25 mcg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3, 12,000 IU daily for 12 weeks
Trial: 18393052
Drug: Methamphetamine administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methamphetamine administration
Trial: 16581036
Drug: Eszopiclone 3
RxNorm normalized name: eszopiclone 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eszopiclone 3 mg co-administered with fluoxetine
Trial: 16581036
Drug: Placebo co-administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo co-administered with fluoxetine
Trial: 31818716
Drug: OLA-guided therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OLA-guided therapy
Trial: 16850671
Drug: Low-dose monophasic
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose monophasic oral contraceptive pills
Trial: 2876775
Drug: Tulobuterol (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tulobuterol (2 mg BID)
Trial: 2876775
Drug: Salbutamol (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salbutamol (2 mg TID)
Trial: 8583779
Drug: Epoprostenol infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epoprostenol infusion (initial rate of 2 ng/kg/min, increased to max 8 ng/kg/min)
Trial: 2248854
Drug: 15 ml
RxNorm normalized name: ethanol 0.15 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 ml kg‐1 h‐1 intravenous crystalloid fluid
Trial: 2248854
Drug: 5-10 ml
RxNorm normalized name: amlodipine
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5-10 ml kg‐1 h‐1 intravenous crystalloid fluid
Trial: 2248854
Drug: Low sodium
RxNorm normalized name: Slow Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low sodium (glucose) solutions
Trial: 6988946
Drug: Doxycycline 200
RxNorm normalized name: doxycycline 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline 200 mg orally 12‐18 hours preoperatively and 200 mg intravenously during the subsequent 4 days
Trial: 6988946
Drug: Doxycycline 200
RxNorm normalized name: doxycycline 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline 200 mg orally 12‐18 hours preoperatively and 200 mg intravenously during the subsequent 4 days + 2 grams of tinidazole orally as a single dose 12‐18 hours preoperatively
Trial: 6988946
Drug: Bacitracin/neomycin tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bacitracin/neomycin tablets during the 3 days immediately prior to operation
Trial: 26296929
Drug: OTO‐201 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OTO‐201 4 mg
Trial: 26296929
Drug: OTO‐201 12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OTO‐201 12 mg
Trial: 24482348
Drug: Postoperative prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative prednisone 30 mg daily × 7 days
Trial: 24482348
Drug: Postoperative placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative placebo pill daily × 7 days
Trial: 23188903
Drug: Peri-articular injection
RxNorm normalized name: casanthranol / docusate sodium Oral Capsule [Peri-Colace]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peri-articular injection of local anaesthetic
Trial: 15168035
Drug: All solutions
RxNorm normalized name: ALCOHOL 0.57 mL in 1 mL / IODINE 0.06 g in 1 mL / POTASSIUM IODIDE 0.05 g in 1 mL / BORIC ACID 0.01 g in 1 mL / SODIUM BORATE 0.002 g in 1 mL TOPICAL LINIMENT [Ball Solutions]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All solutions (WHY, CAHY, C, W)
Trial: 10022937
Drug: Systemic antiedema
RxNorm normalized name: Drugs used in hereditary angioedema
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic antiedema and hemostyptic therapy (Dicynone drg and Reparil drg)
Trial: 2189367
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose beclomethasone dipropionate (750 micrograms three times daily for five days)
Trial: 2511911
Drug: Atenolol 50
RxNorm normalized name: atenolol 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol 50 mg twice daily
Trial: 389223
Drug: Atenolol (any
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol (any dosage)
Trial: 101223
Drug: Atenolol once
RxNorm normalized name: Atenolol
DrugBank: Atenolol (DB00335)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atenolol once daily
Trial: 30944686
Drug: 0.2 mg
RxNorm normalized name: niacin 0.2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg hydromorphone coadministered with ropivacaine (group H1)
Trial: 30944686
Drug: 0.4 mg
RxNorm normalized name: biotin 0.4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 mg hydromorphone coadministered with ropivacaine (group H2)
Trial: 30944686
Drug: 0.6 mg
RxNorm normalized name: thymol 0.6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.6 mg hydromorphone coadministered with ropivacaine (group H3)
Trial: 30944686
Drug: 0 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 mg hydromorphone coadministered with ropivacaine (group H0)
Trial: 28288592
Drug: treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: treatment as usual without specific training (tauSTPP)
Trial: 25939591
Drug: 1,000 mg
RxNorm normalized name: bran 1,000 mg ORAL WAFER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,000 mg resveratrol daily for 4 months
Trial: 23297849
Drug: Removable dentures
RxNorm normalized name: ALCOHOL,DENATURED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Removable dentures supported with four implants
Trial: 23297849
Drug: Fixed reconstruction
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed reconstruction using eight implants
Trial: 23297849
Drug: Various implant
RxNorm normalized name: various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Various implant retained and/or supported prostheses
Trial: 20571097
Drug: Low-GDP solution
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-GDP solution
Trial: 17449110
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of amantadine 100 mg t.i.d. and baclofen 30 mg t.i.d.
Trial: 17449110
Drug: Cocaine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cocaine (20 mg and 40 mg doses)
Trial: 14680448
Drug: Carvedilol (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carvedilol (mean daily dose 41.8 mg)
Trial: 14680448
Drug: Metoprolol tartrate
RxNorm normalized name: Metoprolol Tartrate
DrugBank: Metoprolol (DB00264)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metoprolol tartrate (mean daily dose 85 mg)
Trial: 8749837
Drug: Lofepramine (noradrenaline-specific
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lofepramine (noradrenaline-specific reuptake inhibitor)
Trial: 8749837
Drug: Fluoxetine (serotonin-specific
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (serotonin-specific reuptake inhibitor)
Trial: 27543832
Drug: female‐specific group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: female‐specific group or individual outpatient treatment
Trial: 22945607
Drug: Oral iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral iron supplementation (50 mg, 4 times a week for 8.5 months)
Trial: 11232677
Drug: Nasogastric administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nasogastric administration of SOS (40 mg dose)
Trial: 11232677
Drug: Jejunal/duodenal administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jejunal/duodenal administration of SOS (40 mg dose)
Trial: 11232677
Drug: All routes
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All routes of administration (nasogastric, jejunal, duodenal)
Trial: 9490600
Drug: Thyroxine suppressive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thyroxine suppressive therapy
Trial: 9490600
Drug: Postoperative thyroxine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative thyroxine therapy
Trial: 9490600
Drug: Monitoring without
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Monitoring without thyroxine treatment
Trial: 7817355
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg trandolapril once daily for 30 days (D21 to D50)